EDIT News and Press, Editas Medicine Inc. From 04/27/23

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to EDIT-301, an investigational, gene editing medicine, for the trea...

2023-04-17 14:50:38 ET Shares of clinical-stage biotech Editas Medicine (NASDAQ: EDIT) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also benefited from the news last week that the company was appointing ...

2023-04-16 09:00:00 ET Price is sometimes seen as an indicator of quality in equity markets. After all, if a company has excellent prospects, investors will flock to its shares, bidding them up. That's why corporations with relatively low per-share prices are often considered less secure an...

2023-04-13 15:59:42 ET Shares of gene editing companies rose Thursday as Wall Street took notice of the underperforming subsector issuing a series of bullish views despite the recent selloff. Notable gainers include Editas Medicine ( NASDAQ: EDIT ), Sangamo Therapeutics ( SG...

2023-04-13 09:24:10 ET Editas Medicine ( NASDAQ: EDIT ) has announced the appointment of current Independent Director Emma Reeve as Chair of the Board, effective at the Co.’s next annual stockholder meeting, currently scheduled for June 1. Ms. Reeve will be rep...

Emma Reeve to support Editas’ evolution in new role as Chair of the Board Elliott Levy, M.D., joins Board as an Independent Director CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, toda...

2023-04-13 05:25:00 ET AMC Entertainment (NYSE: AMC) , SNDL (NASDAQ: SNDL) , Netflix (NASDAQ: NFLX) , Editas Medicine (NASDAQ: EDIT) , and Tilray Brands (NASDAQ: TLRY) are some of the more popular stocks among retail investors. With the exception of E...

2023-04-06 06:30:00 ET Editas Medicine (NASDAQ: EDIT) and Bluebird Bio (NASDAQ: BLUE) are both beaten-down gene-editing stocks. Editas' shares are down by 65% in the last 12 months, whereas Bluebird's have fallen by 40%. The question of which company is the better gene-e...

2023-04-03 06:00:00 ET Editas Medicine (NASDAQ: EDIT) sits at the bleeding edge of biotech's hottest field, gene editing to treat inherited diseases. The company has shifted its focus to a product it is testing for severe sickle cell disease, an affliction that disproportionately af...

2023-03-30 08:45:00 ET There's a lot of excitement around the potential for gene-editing stocks because their therapies have the potential to not only treat diseases, but cure them. One such company is Editas Medicine (NASDAQ: EDIT) . Editas focuses on CRISPR (clustered, reg...